GeoVax Labs Inc GOVX.OQ GOVX.O is expected to show a rise in quarterly revenue when it reports results on March 27 for the period ending December 31 2024
The Smyrna Georgia-based company is expected to report revenue of $2.38 million, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for GeoVax Labs Inc is for a loss of 77 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for GeoVax Labs Inc is $15.00, above its last closing price of $1.40.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.43 | -1.48 | -0.91 | Beat | 38.4 |
Jun. 30 2024 | -2.51 | -3.36 | -1.99 | Beat | 40.9 |
Mar. 31 2024 | -5.56 | -5.56 | -2.47 | Beat | 55.6 |
Dec. 31 2023 | -2.27 | -2.78 | -13.60 | Missed | -389.8 |
Sep. 30 2023 | -3.60 | -3.60 | -4.80 | Missed | -33.3 |
Jun. 30 2023 | -2.45 | -2.47 | -3.30 | Missed | -33.3 |
Mar. 31 2023 | -3.05 | -3.05 | -2.25 | Beat | 26.2 |
Dec. 31 2022 | -3.75 | -3.00 | -3.00 | Met | 0 |
This summary was machine generated March 25 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。